share_log

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A：证券上市注册声明(修正)
美股sec公告 ·  05/06 17:30
Moomoo AI 已提取核心信息
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment relates to a proposed offering of up to 3,322,259 shares of common stock, along with Pre-Funded Warrants and Series B-1 and Series B-2 Common Warrants to purchase an equal number of shares. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities required to be sold. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'TTOO.' The offering aims to raise capital for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close on or about May 15, 2024, subject to customary closing conditions.
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment relates to a proposed offering of up to 3,322,259 shares of common stock, along with Pre-Funded Warrants and Series B-1 and Series B-2 Common Warrants to purchase an equal number of shares. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities required to be sold. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'TTOO.' The offering aims to raise capital for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close on or about May 15, 2024, subject to customary closing conditions.
T2 Biosystems是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者，已于2024年5月6日向美国证券交易委员会（SEC）提交了其S-1表格注册声明的修正案。该修正案涉及拟发行最多3,322,259股普通股，以及预先筹资的认股权证以及B-1系列和B-2系列普通认股权证，以购买相同数量的股份。此次发行以 “合理的最大努力” 为基础，不要求出售最低数量的证券。该公司的普通股在纳斯达克资本市场上市，股票代码为 “TTOO”。此次发行旨在为营运资金和一般公司用途筹集资金，包括销售和营销、制造和临床开发成本。此次发行预计将于2024年5月15日左右结束，但须遵守惯例成交条件。
T2 Biosystems是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者，已于2024年5月6日向美国证券交易委员会（SEC）提交了其S-1表格注册声明的修正案。该修正案涉及拟发行最多3,322,259股普通股，以及预先筹资的认股权证以及B-1系列和B-2系列普通认股权证，以购买相同数量的股份。此次发行以 “合理的最大努力” 为基础，不要求出售最低数量的证券。该公司的普通股在纳斯达克资本市场上市，股票代码为 “TTOO”。此次发行旨在为营运资金和一般公司用途筹集资金，包括销售和营销、制造和临床开发成本。此次发行预计将于2024年5月15日左右结束，但须遵守惯例成交条件。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息